Artiva Biotherapeutics (ARTV) executive auto-sells 7,002 shares to cover RSU taxes

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. reported that Chief Tech Operations Officer Christopher Horan sold 7,002 shares of common stock on May 19, 2026 at a weighted average price of $9.0078 per share. The price range for these sales was between $8.7421 and $9.0104.

According to the company’s sell-to-cover policy, these automatic sales were made solely to cover tax withholding obligations arising from the vesting and release of restricted stock units, and were not discretionary trades. After the transaction, Horan directly owned 293,450 shares of Artiva common stock.

Insights

Routine automatic tax-related sale with substantial holdings retained.

The transaction involves 7,002 shares of Artiva Biotherapeutics common stock sold at a weighted average of $9.0078 on May 19, 2026. Footnotes state the company uses a sell-to-cover policy for tax withholding on restricted stock unit vesting.

The filing explains these sales were automatic and not at Christopher Horan’s discretion, framing them as a mechanical consequence of equity compensation rather than an active portfolio decision. Following the sale, he still directly holds 293,450 shares, indicating the transaction is small relative to his remaining stake.

Because the sale is tied to tax obligations and retains a large continuing position, it generally carries limited informational value about management’s view of the stock, and functions mainly as routine administration of equity awards.

Insider Trade Summary

Net Seller: 7,002 shares ($63,073)

Net Sell 1 txn

Insider Horan Christopher

Role Chief Tech Operations Officer

Sold 7,002 shs ($63K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,002	$9.0078	$63K

Holdings After Transaction: Common Stock — 293,450 shares (Direct)

Footnotes (1)

The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7421 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 7,002 shares Weighted average sale price: $9.0078 per share Sale price range: $8.7421–$9.0104 per share +2 more

5 metrics

Shares sold 7,002 shares Common stock sold on May 19, 2026

Weighted average sale price $9.0078 per share Open-market sales to cover tax withholding

Sale price range $8.7421–$9.0104 per share Price range for reported transactions

Shares owned after transaction 293,450 shares Direct holdings following the May 19, 2026 sale

Net shares sold 7,002 shares Net-sell direction in transaction summary

Key Terms

sell-to-cover policy, restricted stock units, weighted average sale price, open-market sale

4 terms

sell-to-cover policy financial

"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations"

restricted stock units financial

"in connection with the vesting and release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $9.0078"

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 05/19/2026 - 09:52 PM Accepted by SEC EDGAR 05/19/2026 - 09:52 PM

FAQ

What insider transaction did Artiva Biotherapeutics (ARTV) report for Christopher Horan?

Artiva Biotherapeutics reported that executive Christopher Horan sold 7,002 shares of common stock on May 19, 2026, at a weighted average price of $9.0078. The sale was automatic under a sell-to-cover policy to satisfy tax withholding tied to restricted stock unit vesting.

Why did Christopher Horan sell Artiva Biotherapeutics (ARTV) shares in this Form 4?

The shares were sold to cover tax withholding obligations from vesting restricted stock units under Artiva’s sell-to-cover policy. Footnotes clarify the sales were automatic, intended solely to satisfy taxes, and were not made at Horan’s discretion as a voluntary trading decision.

How many Artiva Biotherapeutics (ARTV) shares does Christopher Horan hold after the reported sale?

After selling 7,002 shares, Christopher Horan directly holds 293,450 shares of Artiva Biotherapeutics common stock. This indicates he retains a substantial ownership position following the tax-related transaction reported, which was associated with the vesting and release of restricted stock units.

At what prices were the Artiva Biotherapeutics (ARTV) shares sold in this insider transaction?

The weighted average sale price for the 7,002 shares was $9.0078 per share. Footnotes note the individual sale prices ranged between $8.7421 and $9.0104, and detailed breakdowns by price level are available upon request from the company, SEC staff, or shareholders.

Does the Form 4 suggest this Artiva Biotherapeutics (ARTV) sale was discretionary trading?

The Form 4 states the issuer has a sell-to-cover policy and that the reported sales were automatic to cover tax withholding on restricted stock units. It specifically notes the transactions were not at Christopher Horan’s discretion, distinguishing them from voluntary open-market selling decisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horan Christopher

(Last)

(First)

(Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Tech Operations Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/19/2026		S		7,002⁽¹⁾	D	$9.0078⁽²⁾	293,450	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7421 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Andrew Cronauer, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR